Edwards Lifesciences Corp (EW)vsGlucoTrack Inc (GCTK)
EW
Edwards Lifesciences Corp
$86.29
+0.65%
HEALTHCARE · Cap: $50.87B
GCTK
GlucoTrack Inc
$1.82
-29.46%
HEALTHCARE · Cap: $2.04M
Smart Verdict
WallStSmart Research — data-driven comparison
EW leads profitability with a 15.4% profit margin vs 0.0%. GCTK trades at a lower P/E of 0.1x. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
GCTK
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.8%
Fair Value
$254.09
Current Price
$86.29
$167.80 discount
Intrinsic value data unavailable for GCTK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Strong operational efficiency at 29.8%
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : GCTK
The strongest argument for GCTK centers on P/E Ratio, Debt/Equity.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 52.5x leaves little room for execution misses.
Bear Case : GCTK
The primary concerns for GCTK are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
EW profiles as a mature stock while GCTK is a value play — different risk/reward profiles.
EW carries more volatility with a beta of 0.85 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 27/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →GlucoTrack Inc
HEALTHCARE · MEDICAL DEVICES · USA
GlucoTrack, Inc., a medical device company, designs, develops and markets noninvasive glucose monitoring devices for people with diabetes and prediabetes in Europe and Asia Pacific. The company is headquartered in Or Yehuda, Israel.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?